|
**Overview**: Growth Hormone Stimulation Panel**Introduction**: The Growth Hormone Stimulation Panel is a diagnostic tool designed to assess growth hormone response using serum samples. In India, growth hormone deficiency (GHD) affects ~1 in 4,000â€"10,000 children, contributing to short stature in ~3-5 percent of pediatric population, with underdiagnosis common in rural/low-SES children presenting with poor height velocity, delayed bone age, or hypoglycemia. High morbidity from delayed GH therapy leading to permanent short stature, reduced quality of life, and psychosocial issues. Per endocrinology practices aligned with ICMR and Indian Society for Pediatric and Adolescent Endocrinology guidelines, the test employs immunoassay for basal GH and post-stimulation GH levels (multiple time points after insulin/clonidine/GHRH stimulation) over 1-2 days with high accuracy, valuable for confirming GHD in children failing to meet height standards. This diagnostic falls under hormonal screening and targets children with short stature or suspected pituitary dysfunction, addressing accurate detection to guide recombinant GH therapy and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise GH axis evaluation and improving height outcomes. Its serum-based approach ensures reliable dynamic hormone measurement.**Other Names**: GH Stim Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: GH stimulation testing standard; in India, used in pediatric endocrine clinics.**Purpose**: The test assesses 4 parameters including basal GH to guide growth hormone response evaluation, confirm deficiency, inform GH therapy.**Test Parameters**: 1. Basal GH, 2â€"4. Post-Stimulation GH Levels (3 Time Points).**Pretest Condition**: Fasting 10-12 hours required; patients should be children with short stature.**Specimen**: 3 mL serum in 1 SST (multiple timed draws), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on growth velocity, puberty status, family height.**Consent**: Written informed consent (parental) is required, detailing the test's purpose, potential risks of stimulation (hypoglycemia), benefits of confirming GHD, and minimal discomfort from multiple venipunctures.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret stimulated GH peaks within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols. Stimulation is performed under medical supervision.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or inadequate stimulation can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Subnormal GH peak (<7-10 ng/mL) confirms GHD, necessitating specialist input. Normal response may require follow-up.**Specialist Consultation**: Pediatric endocrinologists should be consulted for management.**Additional Supporting Tests**: IGF-1, bone age X-ray for confirmation.**Test Limitations**: Requires stimulation protocol; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Growth Studies India 2023. |
